Reconsideration of the Benefits of Pharmacological Interventions for the Attenuation of the Cognitive Adverse Effects of Electroconvulsive Therapy.


Journal

The Journal of clinical psychiatry
ISSN: 1555-2101
Titre abrégé: J Clin Psychiatry
Pays: United States
ID NLM: 7801243

Informations de publication

Date de publication:
03 10 2022
Historique:
entrez: 5 10 2022
pubmed: 6 10 2022
medline: 12 10 2022
Statut: epublish

Résumé

The cognitive adverse effects (AEs) of electroconvulsive therapy (ECT) limit the wider use of the treatment. These AEs can be attenuated by changing the way ECT is administered; however, such changes may reduce the response rate, the speed of response, or both. A recent systematic review and meta-analysis identified more than a dozen pharmacologic interventions in 26 randomized controlled trials (RCTs) that sought to reduce ECT-induced cognitive AEs. Because of large differences across RCTs, only a few outcomes for a few interventions could be pooled in meta-analysis, and most pooled analyses included only 2-3 RCTs. Important findings were that acetylcholinesterase inhibitors, ketamine, memantine, and liothyronine were associated with improved global cognitive functioning at 1-14 days post-ECT. Anti-inflammatory treatments and opioid receptor antagonists were not associated with improvement in general cognitive outcome at 1-14 days post-ECT. Meta-analysis was not possible for the remaining interventions, including piracetam, melatonin, pemoline, nortriptyline, herbal agents, drugs acting on the cortisol pathway, opioid receptor antagonists, l-tryptophan, vasopressin analogs, calcium channel blockers, and others; in individual RCTs, some of these interventions attenuated some cognitive measures as some time points after ECT. Regrettably, none of the RCTs examined clinically meaningful outcomes such as subjective cognitive impairment, impairments in daily life, and persistent autobiographical memory deficits. Future research should study such clinically meaningful outcomes (rather than laboratory tests), using pharmacologic interventions, perhaps in combination, for ECT procedures that are associated with higher cognitive AE burden. A risk is that whatever attenuates ECT-induced cognitive AEs may also attenuate ECT-related therapeutic benefits.

Identifiants

pubmed: 36198062
doi: 10.4088/JCP.22f14668
doi:
pii:

Substances chimiques

Calcium Channel Blockers 0
Cholinesterase Inhibitors 0
Narcotic Antagonists 0
Triiodothyronine 06LU7C9H1V
Ketamine 690G0D6V8H
Pemoline 7GAQ2332NK
Tryptophan 8DUH1N11BX
Nortriptyline BL03SY4LXB
Melatonin JL5DK93RCL
Memantine W8O17SJF3T
Hydrocortisone WI4X0X7BPJ
Piracetam ZH516LNZ10

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Copyright 2022 Physicians Postgraduate Press, Inc.

Auteurs

Chittaranjan Andrade (C)

Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bangalore, India (candrade@psychiatrist.com).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH